Scarica l'app Stockscreener
17.69
7.34%
1.21
Dopo l'orario di chiusura:
17.60
-0.09
-0.51%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché SRPT Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$16.48
Aprire:
$16.4
Volume 24 ore:
3.93M
Relative Volume:
0.61
Capitalizzazione di mercato:
$1.85B
Reddito:
$2.48B
Utile/perdita netta:
$-57.96M
Rapporto P/E:
-23.32
EPS:
-0.7585
Flusso di cassa netto:
$-453.97M
1 W Prestazione:
-5.95%
1M Prestazione:
-24.24%
6M Prestazione:
-55.83%
1 anno Prestazione:
-83.99%
Intervallo 1D:
$16.33
$17.72
Intervallo di 1 settimana:
$15.94
$18.70
Portata 52W:
$10.41
$138.81
Sarepta Therapeutics Inc Stock (SRPT) Company Profile
Nome
Sarepta Therapeutics Inc
Settore
Industria
Telefono
617-274-4000
Indirizzo
215 FIRST STREET, CAMBRIDGE, MA
Confronta SRPT con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
17.69 | 1.73B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-11-05 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-09-22 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-07-29 | Iniziato | Bernstein | Mkt Perform |
| 2025-07-29 | Reiterato | H.C. Wainwright | Sell |
| 2025-07-29 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2025-07-29 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2025-07-28 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-07-25 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-07-24 | Iniziato | Citigroup | Sell |
| 2025-07-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2025-07-22 | Downgrade | Barclays | Overweight → Equal Weight |
| 2025-07-21 | Downgrade | Deutsche Bank | Buy → Hold |
| 2025-07-21 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | Downgrade | Mizuho | Outperform → Neutral |
| 2025-07-21 | Downgrade | Needham | Hold → Underperform |
| 2025-07-21 | Downgrade | UBS | Buy → Neutral |
| 2025-07-18 | Downgrade | Needham | Buy → Hold |
| 2025-06-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | Downgrade | TD Cowen | Buy → Hold |
| 2025-06-17 | Iniziato | Wolfe Research | Peer Perform |
| 2025-06-16 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-06-16 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | Downgrade | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | Aggiornamento | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2025-04-11 | Iniziato | Wells Fargo | Overweight |
| 2025-04-02 | Aggiornamento | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2024-11-27 | Reiterato | Needham | Buy |
| 2024-11-25 | Iniziato | H.C. Wainwright | Sell |
| 2024-11-07 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | Iniziato | Jefferies | Buy |
| 2024-10-10 | Ripresa | Raymond James | Outperform |
| 2024-07-29 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | Downgrade | Citigroup | Buy → Neutral |
| 2024-05-31 | Iniziato | Piper Sandler | Overweight |
| 2024-05-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-01-31 | Iniziato | BMO Capital Markets | Outperform |
| 2023-12-13 | Ripresa | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-21 | Iniziato | Wedbush | Outperform |
| 2023-10-31 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-04-26 | Iniziato | SMBC Nikko | Outperform |
| 2023-04-04 | Iniziato | Citigroup | Buy |
| 2023-03-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | Reiterato | BTIG Research | Buy |
| 2022-12-16 | Aggiornamento | UBS | Neutral → Buy |
| 2022-04-04 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-01-05 | Reiterato | Needham | Buy |
| 2021-12-09 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-11-05 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2021-09-15 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-08-05 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-06-15 | Iniziato | BTIG Research | Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Neutral |
| 2021-01-12 | Downgrade | Citigroup | Buy → Neutral |
| 2021-01-11 | Downgrade | UBS | Buy → Neutral |
| 2021-01-08 | Downgrade | JP Morgan | Overweight → Underweight |
| 2021-01-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | Iniziato | Berenberg | Hold |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | Iniziato | Mizuho | Buy |
| 2019-11-01 | Iniziato | Guggenheim | Buy |
| 2019-08-21 | Reiterato | Needham | Buy |
| 2019-07-09 | Reiterato | Morgan Stanley | Overweight |
| 2019-07-01 | Reiterato | RBC Capital Mkts | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-11 | Reiterato | Credit Suisse | Outperform |
| 2018-10-12 | Iniziato | Bernstein | Outperform |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-26 | Reiterato | RBC Capital Mkts | Outperform |
| 2018-09-14 | Ripresa | BofA/Merrill | Buy |
| 2018-09-06 | Iniziato | Credit Suisse | Outperform |
| 2018-08-01 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | Reiterato | Robert W. Baird | Outperform |
| 2018-06-20 | Reiterato | Needham | Buy |
| 2018-06-19 | Reiterato | H.C. Wainwright | Buy |
Mostra tutto
Sarepta Therapeutics Inc Borsa (SRPT) Ultime notizie
Is Sarepta Therapeutics Inc. stock overvalued by current metricsGap Down & Low Drawdown Momentum Ideas - newser.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sarepta Therapeutics, Inc.SRPT - PR Newswire
Will Sarepta Therapeutics Inc. (AB3A) stock test record highs in 2025Weekly Gains Summary & Scalable Portfolio Growth Methods - newser.com
Why Sarepta Therapeutics Inc. (AB3A) stock signals breakout potentialJuly 2025 Action & Verified Swing Trading Watchlist - newser.com
What technical models suggest about Sarepta Therapeutics Inc.’s comeback - newser.com
Sarepta Therapeutics Inc. stock trend forecastJuly 2025 Macro Moves & Smart Allocation Stock Reports - newser.com
Relative strength of Sarepta Therapeutics Inc. in sector analysisJuly 2025 Drop Watch & Growth Focused Stock Reports - newser.com
How Sarepta Therapeutics Inc. (AB3A) stock expands through international markets2025 Key Lessons & Expert Approved Momentum Trade Ideas - newser.com
Is Sarepta Therapeutics Inc. stock ready for a breakoutMarket Growth Report & Low Volatility Stock Recommendations - newser.com
Using Bollinger Bands to evaluate Sarepta Therapeutics Inc.Rate Hike & Safe Capital Growth Trade Ideas - newser.com
Will Sarepta Therapeutics Inc. (AB3A) stock profit from AI boomRecession Risk & Fast Moving Stock Watchlists - newser.com
Is Sarepta Therapeutics Inc. stock attractive for growth ETFs2025 Market WrapUp & Scalable Portfolio Growth Ideas - newser.com
Sarepta Therapeutics Faces Mounting Challenges as Regulatory and Clinical Setbacks Converge - Ad-hoc-news.de
Forecasting Sarepta Therapeutics Inc. price range with options dataTrade Risk Summary & Daily Stock Trend Watchlist - newser.com
Smart tools for monitoring Sarepta Therapeutics Inc.’s price actionJuly 2025 Sector Moves & Fast Gain Stock Tips - newser.com
Is Sarepta Therapeutics, Inc. stock overvalued by current metrics2025 Volatility Report & Safe Capital Growth Stock Tips - newser.com
Gene therapy invented at Children's gets strongest FDA label after patient deathsColumbus Business First - The Business Journals
FDA’s stronger warning on Sarepta gene therapy raises new questions about heart risk - statnews.com
FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings - sharewise.com
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
What to do if you’re stuck in Sarepta Therapeutics Inc.Treasury Yields & AI Enhanced Market Trend Forecasts - newser.com
Sarepta’s DMD drug Elevidys to carry liver failure warning - The Pharma Letter
FDA Imposes Boxed Warning, Narrows Patient Pool for Sarepta’s Duchenne Gene Therapy Elevidys - BioSpace
We Think Sarepta Therapeutics (NASDAQ:SRPT) Has A Fair Chunk Of Debt - 富途牛牛
Sarepta (SRPT) Faces Increased FDA Scrutiny on Elevidys - GuruFocus
Sarepta Stock Slides Premarket After New FDA Warning Shrinks Market For Its $3.2M DMD Gene Therapy - Stocktwits
How to escape a deep drawdown in Sarepta Therapeutics Inc.Market Activity Report & Real-Time Chart Breakout Alerts - newser.com
Sarepta Therapeutics Inc Azioni (SRPT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.38%
1.42%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):